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ABSTRACT
Background: Congestive Heart Failure (CHF) is the most common diagnosis accounting
for more healthcare costs than any diagnosis. CHF readmissions contribute significantly
to this expenditure. Quality of care in heart failure is linked to process based performance
measures. This study evaluated the relationship between adherence to performance
metrics and 30 day readmission rates.
Methods: This was a single center case-control study that evaluated 6063 consecutive
patients admitted with CHF from December 2001 through December 2008. Data was
collected for readmission to the hospital within 30 days and compliance to the heart
failure performance measures at discharge.
Results: The rate of readmission for CHF increased steadily from 16.8% in 2002 to
24.8% in 2008. Adherence to CHF performance measures increased concurrently during
the same time frame from 88.7% to 98.9%.Except for left ventricular function (LVF)
assessment, 30 day readmission rate was not associated with adherence to performance
measures. Readmitted patients had twice the odds of not having their LVF assessed (OR:
2.0; p<0.00005; 95% CI: 1.45-2.63)
Conclusions: Heart failure performance measures, except for the assessment of left
ventricular function have little relationship with 30 day hospital readmissions after
discharge. More studies need to be done to identify performance measures that correlate
with quality of care in heart failure patients.
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INTRODUCTION:
Congestive heart failure (CHF) is a very common and disabling health problem
seen most commonly in patients above 65 years (AHA, 2005; Kannel & Belanger, 1991).
The incidence of CHF increases with age. CHF is a syndrome in which the heart is not
able to meet the body’s metabolic demands thus resulting in a variety of symptoms where
the body suffers from effects of inadequate oxygen. This leads to symptoms such as
shortness of breath, fatigue, poor exercise tolerance and fluid retention in various tissues
of the body. CHF is a major public health problem in the western world. In the US alone
there are about 5 million Americans living with the diagnosis of heart failure. It is also
estimated that another 550,000 Americans are diagnosed with this condition every
year(AHA, 2005). CHF accounts for about 15 million physician office visits every year
(O'Connell & Bristow, 1994). CHF is the most common Medicare discharge diagnosis
accounting for more healthcare costs than any other condition in the US (Massie & Shah,
1997). The overall prevalence of heart failure is increasing as the segment of the elderly
population increases. Hospitalizations with a primary diagnosis of CHF among adults
(age ≥35) increased from 810,624 in 1990 to 989,500 in 1995 and to 1,088,349 in 1999
(Koelling, Chen, Lubwama, L'Italien, & Eagle, 2004).
This increase has been attributed to the aging population and the advances in the
treatment of coronary artery disease (CAD) that have led to more people surviving initial
events of acute myocardial infarction (Senni et al., 1999). CHF is primarily a disease of
the elderly as evidenced by the fact that 80% of the patients admitted with heart failure
are over the age of 65 years (Masoudi, Havranek, & Krumholz, 2002). The incidence of
CHF among people aged 65 years and above is about 10 per 1000 population (Kannel &
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Belanger, 1991). Congestive heart failure is very prevalent and the magnitude of the
problem is such that, it is associated with high healthcare expenditure estimated to be
about over $35 billion per year in the USA (Massie & Shah, 1997; O'Connell & Bristow,
1994). Most of the expenditure is due to frequent readmissions of patients with this
condition. Twenty percent of all patients discharged from the hospital with heart CHF are
readmitted within the first 30 days and 50 % within 6 months (Masoudi et al., 2002;
Senni et al., 1999).
Risk Factors
There are many factors that predispose to heart failure. Hypertension is the
commonest risk factor for heart failure followed by antecedent acute myocardial
infarction (AMI) (Levy, Larson, Vasan, Kannel, & Ho, 1996). The other risk factors
include diabetes, metabolic syndrome, dilated cardiomyopathy, smoking and excessive
alcohol use. Diabetes mellitus increases substantially the risk of developing CHF
especially among post menopausal women with established coronary artery disease. CHF
incidence increases with each additional risk factor, for example, the annual incidence of
CHF among non diabetic women with no risk factors was 0.4%. This risk increased to
3.4% in the non diabetic women with at least 3 traditional cardiovascular risk factors.
Examples of traditional risk factors include diabetes, smoking, hyperlipidemia, and
hypertension. Among diabetic persons with no additional risk factors, the annual
incidence of CHF was 3.0%, compared with 8.2% among diabetics with at least 3
additional risk factors (Bibbins-Domingo et al., 2004).

7
Classification of Heart Failure
There are numerous ways of classifying heart failure and in many cases these
categories overlap and maybe ambiguous. The basis of these definitions have varied
widely and have ranged from, anatomical (right versus left sided heart failure),
physiological (diastolic versus systolic), and in some instances clinical considerations
(acute versus chronic). The World Health Organization (WHO) classification is based on
the nature of myocardial disorder (i.e. dilated, hypertrophic, restrictive, arrhythmogenic
right ventricular and unspecified cardiomyopathies) (Richardson et al., 1996).
In recognition of the fact that heart failure is a progressive disorder, the American
Heart Association (AHA) and the American College of Cardiology (ACC) Societies have
developed in collaboration the staging criteria that takes into account the development
and progression of the disease (Hunt et al., 2001). This classification has 4 stages; A
through D.
Stage A identifies patients that are at high risk for developing heart failure but
have no structural abnormalities of the heart and have no symptoms of heart failure.
These are patients that might have risk factors for developing heart failure such as
hypertension, diabetes, and coronary artery disease, history of alcohol abuse or exposure
to cardio toxins.
Stage B includes patients with structural heart abnormalities but with no overt
symptoms of heart failure. Patients in this stage might have left ventricular hypertrophy
(LVH), reduced left ventricular ejection fraction (LVEF), valvular disease and prior
myocardial infarction but are asymptomatic.
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Stage C includes patients that have all the factors in stages A and B, and in
addition have symptoms of clinical heart failure. They have not only structural
abnormality of the heart but manifests clinical symptoms and signs of clinical heart
failure.
Stage D includes patients that are refractory to standard treatment of heart failure.
These are patients that may require intravenous medications, on an outpatient basis, that
help stimulate the contraction of the heart. The other modalities of treatment for this stage
include mechanical assist devices, heart transplant or hospice care.
In the ACC/AHA staging of heart failure, a classification that takes into account
the severity and progression of heart failure, patients can progress from one lower stage
to a higher stage but never the reverse, i.e. from stage A to B and never from B to A.
There is another more clinically based classification or staging of heart failure called the
New York Heart Association (NYHA) classification. This classification of heart failure
uses the presence or absence of symptoms of heart failure on functional capacity to
classify severity of heart failure (Gibelin, 2001). There are 4 classes in this classification I
through IV.
Class I

No Limitation of physical activity. Ordinary physical activity does
not cause undue fatigue or dyspnea

Class II

Slight limitation of physical activity. Comfortable at rest, but
ordinary physical activity results in fatigue or dyspnea.

Class III

Marked limitation of physical activity. Comfortable at rest, but less
than ordinary activity results in fatigue, palpitation or dyspnea.
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Class IV

Unable to carry on any physical activity without discomfort.
symptoms at rest.

Path Pathophysiology of Heart Failure
There have been numerous conceptual models that have been proposed to explain
heart failure; however, no one single model effectively explains the complexity of the
heart failure syndrome. Earlier models conceived heart failure as a result of excessive salt
and water retention leading to poor renal flow (cardio renal model) (Packer, 1992).
Following this, there was the hemodynamic model which conceived heart failure as a
problem of “pump failure” with resultant excessive peripheral vasoconstriction (Mann &
Bristow, 2005). These models could not, however explain the progression of heart failure
once the original insult causing heart failure was removed. More recently, the “neuro
hormonal model” has attempted to explain the progression of heart failure as resulting
from the effects of biochemical molecules released in response to injury of the heart
(Bristow, 1984). These biomedical chemicals include catecholamine’s, through the
activation of the adrenergic nervous system (ANS); angiotensin II and aldosterone
through the activation of the rennin-angiotensin-aldosterone system (RAAS). With a
reduction in the cardiac output resulting from an insult on the heart (index event),
compensatory mechanisms are set in motion with the goal of maintaining adequate
cardiac output for tissue perfusion. An activated autonomic nervous system and rennin
angiotensin -aldosterone system results in the over expression of catecholamine’s, (also
known as the “flight hormones”), angiotensin II and aldosterone respectively. These
biochemical molecules have profound maladaptive effects on myocardial cells (Bristow,
1984). Some of these effects include loss of cardiac cells, hypertrophy and scaring of the
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cardiac muscle (also known as remodeling). The overall result is that the heart
configuration changes from the elliptical shape to a more spherical shape which is less
efficient in pumping out blood. Patients may be asymptomatic after the index event but
with persistence of these maladaptive changes, patients develop overt symptoms of heart
failure. Therapeutic agents such as beta blockers (BB) and angiotensin converting
enzyme inhibitors (ACEI) have been shown to improve survival in heart failure by
ameliorating the effects these maladaptive changes directly through the ANS and RAAS
respectively(Currie et al., 1984; Fox et al., 2001; Ikram & Fitzpatrick, 1981). This
conceptual frame work helps to explain the changes in the development of systolic
dysfunction (heart failure with depressed ejection fraction, less than 45%). However, the
maladaptive changes in diastolic dysfunction (heart failure with preserved ejection
fraction) are not very well understood.
LITERATURE REVIEW:
Review of Evidence for Medical Treatment of CHF
The treatment for heart failure is divided in to acute phase and maintenance phase.
In the acute phase, the main goals are resuscitative, symptom relief and restoration of the
normal physiology. The maintenance phase (or implementation phase) involves the
administration of life saving treatments that have been shown to improve outcomes in
patients with heart failure. There are some medications that have been shown to reduce
mortality of heart failure patients and these include, angiotensin converting enzyme
inhibitors (ACEI), and beta blockers (BB).Other medications that have scientifically
improved outcomes are aldosterone receptor blockers (ARBS) and aldosterone
antagonists.
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ACE inhibitors
ACEI are a group of medications that inhibit the conversion of angiotensin I to
angiotensin II. Angiotensin II has been implicated in long-term deleterious effects on the
heart and hence suppression of this enzyme has important clinical implications in patients
with heart failure.
The use of ACEI is recommended for most patients with stage B, C, D. These
classes of medications have been shown to confer survival benefit to patients with heart
failure, after myocardial infarction, improve heart failure symptoms and reverse
remodeling by blunting the activity of the RAAS (Garg & Yusuf, 1995; Khalil, Basher,
Brown, & Alhaddad, 2001; Munzel & Keaney, 2001). The effects of these medications
are not dose dependent. The effects of low dose ACEI on mortality has not been any
different than in those patients taking high dose regimens in most randomized clinical
trials (Packer, 1992; Tang et al., 2002).
Beta Blockers (BB)
The other class of medications that has been shown to be beneficial in patients
with heart failure are beta blockers. Beta blockers have been shown to confer clinical
benefits in patients with all stages of heart failure. The benefits that beta blockers confer
include survival, morbidity, and quality of life, rate of hospitalizations, remodeling and
incidence of sudden cardiac death (Farrell, Foody, & Krumholz, 2002; Foody, Farrell, &
Krumholz, 2002). Studies have shown improvements in the systolic function and reversal
of remodeling with just 3 to 4 months of treatment with beta blockers (Bristow, 2000;
Groenning et al., 2000; Krum et al., 2003). In some cases the improvement in mortality
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and hospitalization were seen as early as 14 to 21 days after initiation of therapy (Krum et
al., 2003).
Beta blockers are medications that reduce the effect of sympathetic activity on the
heart and blood vessels by blocking the action of these “flight hormones” on the heart
and blood vessels. An overactive sympathetic activity has been shown to lead to
deleterious effects on the heart. Blunting the effect of these catecholamine’s in patients
with heart failure leads to improved outcomes in both morbidity and mortality rates.
Angiotensin receptor blockers (ARBS)
Angiotensin receptor blockers block the actions of the enzyme angiotensin II at
the angiotensin II type 1 receptor site. Angiotensin receptor blocker are comparable, but
not superior to angiotensin converting enzyme inhibitors (Cohn & Tognoni, 2001;
McMurray, Pfeffer, Swedberg, & Dzau, 2004; Pitt et al., 2000). There are reports of
increased adverse events in patients who were receiving combination of both these
medications rather than one or the other (Baruch et al., 1999; McMurray et al., 2003).
Angiotensin receptor blockers are therefore generally recommended in patients who are
not able to tolerate angiostensin converting enzymes inhibitors, such as cough
angioedema.
Aldosterone antagonist
Aldostereone antagonists are another class of medications that have a beneficial
role in heart failure (McMurray & O'Meara, 2004). Patients with heart failure have
elevated levels of the hormone aldosterone which leads to salt and water retention. Salt
and water retention contribute to worsening of heart failure. Aldosterone also works
locally on the heart muscle inducing myocardial scaring and hypertrophy. Aldosterone
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antagonist counteracts these effects thereby inhibiting the remodeling process (Weber,
2001). Randomized controlled studies have shown that adding these agents to the drug
regimen of patients with advanced heart failure (New York heart classification class III
or IV) improves mortality outcomes and hospital admissions for heart failure (Pitt et al.,
1999).
Causes of heart failure
The most common cause of heart failure in the western world is attributed to
coronary artery disease and may often be secondary to an acute myocardial infarction.
Coronary artery disease accounts for about 70% of the cases of heart failure (Fox et al.,
2001). Heart failure can also result from non ischemic causes such as hypertension,
cardiomyopathies, heart valvular disorders, pericardial disorders or arrhythmias.
Review of evidence on CHF readmissions
Readmissions to the hospital for heart failure may be influenced by multitudinous
factors such as the severity and stage of the illness, preexisting co-morbid conditions,
compliance to prescribed medications, and diet. Other predictors of early readmission to
the hospital include uncoordinated discharge medications, such that the patient may not
be taking the newly adjusted dosages of heart failure medications initiated in the hospital
and may in fact resume the preadmission medications which may have been inadequate
to treat the heart failure condition to begin with. This is otherwise known as post hospital
discharge medications discrepancy (Coleman, Smith, Raha, & Min, 2005). Unco
ordinated discharge plans between hospital physician and primary care physicians in the
communities have been associated with the increased hospital readmission. Rich and
colleagues found that nurse led multidisciplinary coordinated care reduced readmission of
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heart failure by as much as 28 percent (Rich et al., 1995). Another study by Philips and
colleagues showed that post discharge support in elderly patients showed favorable
outcomes and reduced readmissions (Phillips et al., 2004) .
Demographic predictors
Race can be a relevant predictor of hospital readmissions. Studies have shown
that Blacks in general do not seek healthcare early and are more prone to readmissions
than their White counterparts (Evangelista, Dracup, & Doering, 2002; Rathore et al.,
2003). The impact of gender on readmissions is unclear because some studies suggest
that males are more likely to be readmitted than females (Sueta, Schenck, Chowdhury,
Hall, & Simpson, 2000), while other studies suggest that females have higher rates of
readmission Alonso Martinez, Llorente Diez, Echegaray Agara, Urbieta Echezarreta, &
Gonzalez Arencibia, 2001). Independent of sex and gender, hospital readmissions
increase with age greater than 65 years of age (Kossovsky et al., 2000; Krumholz et al.,
2000).
Compliance to medications in the outpatient setting may also be related to quality
of discharge planning.
Co-morbid conditions
The associated co-morbid conditions are also associated with readmission rates of
heart failure. Conditions such as chronic kidney disease, pulmonary disease,
hypertension and diabetes can predispose patients to readmissions (Tsuchihashi et al.,
2001). A study by Brausntsein and colleagues (2003) found that about 40 % of patients
with heart failure have at least 5 non cardiac co-morbidities and these account for about
80% of the healthcare cost for all patients with heart failure.
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Clinical Variables
Certain clinical variables are associated with increased hospitalizations. Some of
these variables include, low cardiac functional status or reserve. The lower the ejection
fraction or cardiac reserve, the higher the severity of heart failure and higher the
likelihood of readmissions. Another clinical variable that may impact readmissions is the
NYHA classification of heart failure. Higher stages of the NYHA imply advanced
disease and therefore will lead to increased length of stay of patients in the hospital
(Philbin & Roerden, 1997).
Medications
Studies are conflicted on the impact of CHF medications on hospital
readmissions. ACEI use have been shown to reduce readmissions (Holst et al., 2001). On
the other hand, the impact of beta blockers is mixed, with some studies suggesting that,
beta blockers reduce hospital readmissions while other studies suggest that, they do not
impact the rates of readmissions (Cobelli, 2000; McDonald et al., 2001).
Process of care
There is evidence to suggest that the process of care of patients with CHF can
affect their outcomes. Some studies have shown that involvement of the cardiologist in
the care of patients while they are in the hospital reduces the length of stay in the hospital
and subsequent rates of readmission (Cobelli, 2000; McDonald et al., 2001; Polanczyk,
Newton, Dec, & Di Salvo, 2001). There is also data to show that the quality of outpatient
management of heart failure affects the rates of readmissions (Kossovsky et al., 2000). A
multidisciplinary approach to the management of patients with heart failure has been
shown to lead to reduced readmissions to the hospital (Stewart, Marley, & Horowitz,
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1999). This is in keeping with the complexities of variables that may affect heart failure
readmissions. Variables that reduce readmissions may range from timely follow up visits
with the primary care physicians and early symptom recognition (Evangelista, Dracup, &
Doering, 2000). Rich and colleagues (1995) reported in their study that a nurse directed
multidisciplinary intervention, involving diet education; prescription medications and
follow-up coordination resulted in reduced readmissions and lower cost of care in
patients with heart failure. The interventions were much more effective in the elderly
patients.
McDonald and colleagues (2002) also validated these results indicating that
patients receiving a multidisciplinary intervention had better outcomes in terms of
readmissions and death compared to the group that had optimized medical care only.
Psychosocial factors
Patients’ psychosocial conditions can also affect the readmissions to the hospital.
Low social economic class, single marital status and depression have been associated
with increased rates of readmissions (Philbin, Dec, Jenkins, & DiSalvo, 2001). Vansuch
and colleagues reported that discharge instructions to patients with heart failure as well as
patient education does reduce the number of readmissions and mortality due to CHF
(VanSuch, Naessens, Stroebel, Huddleston, & Williams, 2006).
National Quality Measures
Healthcare organizations are required to collect information on the delivery of
healthcare services to evaluate the quality of their services as well as report outcomes to
third party payers as well as to credentialing organizations. The two most important
organizations that mandate healthcare reports are the Center for Medicare Services
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(CMS) and the Joint Commission on Accreditation of Healthcare organizations (JCAHO)
also known as the Joint Commission. CMS is a federal government program which serves
as a payer for healthcare services rendered on behalf of its Medicare and Medicaid
patients. The Joint Commission on the other hand is a private sector, not for profit
organization that credentials hospitals and healthcare organization in the US.
Accreditation by the Joint Commission is a requirement if the healthcare
organization is to get reimbursement for services rendered on behalf of Medicare and
Medicaid patients. Hospitals accredited by the Joint Commission are required to assess
quality using prescribed measures called core measures for specific diseases. Heart
failure is one of the diseases the hospital can choose to assess. These measures are based
on peer reviewed studies which provide evidence of the association of the measure with
clinical outcomes. Some of the measures are based on expert consensus opinion. For
heart failure, the core measures are: Assessment of left ventricular function (LVF),
Prescription of ACEI to patients with low, provision of adult smoking cessation advice
for patients that smoke. The other measure is based on expert consensus opinion and is
based on documentation that patients received discharge instructions or educational
materials on six metrics which include: activity, weight, diet, and discharge medications,
follow up appointments and worsening of symptoms (Hunt et al., 2001).
CMS in the early 1990s transitioned from merely acting as a payer of services for
its clients to an insurer also focused on quality of care. This led to a series of quality
initiatives aimed at improving the quality of healthcare that its beneficiaries were
receiving. In 2003 the Center for Medicare Service (CMS) initiated a program called
Hospital Quality Incentive Demonstration Project (HQIDP) with the goal to improving
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quality of care services in the hospitals. In this program, hospitals adhering to evidence
based practices are rewarded with increased payments on Medicare patients. Participating
hospitals have CHF discharge teams or planners to assure adherence with evidence based
guidelines in heart failure prior to discharge from the hospital. Thus hospitals are
expected to monitor and report to CMS the number of patients discharged on ACEI, left
ventricular function assessment, smoking cessation counseling, and discharge instructions
on for heart failure. These variables constitute the “core measures” on patients discharge
from the hospital with heart failure.
Early readmission of heart failure has been linked to quality of care, with
suggestion that patients being readmitted have poor quality of care (Ashton, Kuykendall,
Johnson, Wray, & Wu, 1995). Other studies have not shown such a link between early
hospital readmissions and quality of care for patients with heart failure (Kossovsky et al.,
2000). The CMS however, does not reimburse hospitals for the care of patients who are
readmitted within a period of 30 days. The reimbursement is bundled up with the prior
hospitalization. It is imperative therefore for hospitals to prevent early readmissions for
heart failure. Most hospitals track patients with heart failure that are readmitted within
this 30 days period for administrative purposes. It is important for hospitals to keep such
administrative records for planning purposes to minimize non-reimbursable care.
OBJECTIVES:
The aim of this study is to:
1.

Investigate the rates of adherence to the heart failure performance measures in

patients discharge with heart failure in a community hospital from 2002-2008.
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2.

Study the relationship between hospital adherence to heart failure performance

measures and rates of 30 day readmissions in patients discharged from the hospital with
heart failure.
Study Research Question: The primary research question of this study is: Does
adherence to heart failure performance measure at discharge from the hospital translate to
reduced 30 day readmissions?
STUDY DESIGN:
Methods
This is a retrospective descriptive study designed to compare the rates of early
readmission among patients with heart failure before and after the implementation of
discharge planning strategies in 2005 at the Kettering Medical Center in Ohio. Early
readmission is defined as readmission to the hospital within 30 days of discharge from
the hospital. Subjects include all the patients with CHF who were readmitted at the
hospital between years 2001-2008. Readmission is defined as admission to the hospital
within 30 days of discharge from the hospital.
All patients admitted to the hospital between December 2001 and December 2008
were reviewed. There were total 6,065 patients admitted with the diagnosis of heart
failure. These patients were identified from the heart failure registry using the diagnostic
related group (DRG) codes ascribed for heart failure. From this composite, data of
patients that were admitted for heart failure, and data from patients who had presented to
the hospital within 30 days of discharge were discriminated by the unique medical record
numbers that are assigned to patients with a 30 day readmission for heart failure.
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Data were extracted from the electronic medical records for patients who had met
readmission eligibility. Data collected included demographic information, co morbid
conditions, diagnostic tests, pre-admission and post discharge medications and adherence
to heart failure core measures at discharge. Both the Kettering Medical Center and the
Wright State University’s Institutional Review Boards reviewed and approved this study.
Statistical Analysis
Categorical variables are expressed as numbers and percentages while continuous
variables are expressed as means. The chi-square test was used to measure association
between variables, and to describe the relationship between the heart failure performance
variables and the dependent variable (readmission rate). Statistical significance was set at
p<0.05. Crude rate of readmissions were calculated by dividing the number of 30 day
readmissions by the total number of heart failure admissions during the specified time
interval. Data was imported into Excel worksheet for descriptive statistical analysis of
categorical variables. Chi-square test using the Epi Info® program was used to identify
associations between independent and dependent variables.
RESULTS:
There were 6,063 patients admitted for heart failure between December 2001 and
December 2008. During this time 19.6% (1,191) of the patients were re admitted to the
hospital within 30 days of discharge (see Figure 1) .The baseline characteristics of the
study group are as shown Table 1. The average age of patients was 77.4 (SD 11.2).
55.6% of the patients were female.
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Table1. Patient Characteristics
Female

52.6%

Male

47.4%

Age (Mean)

77.4 (SD 11.2)

HTN

76.8%

CAD

74.0%

CVA

74%

PVD

70.3%

Diabetes

73.8 %

Smokers

62.3%

The patients admitted for heart failure were more likely to have other co-morbid
conditions reflecting the fact that CHF is disease of the elderly with multiple risk factors.
Two-thirds (76.4%) of the study population had hypertension, while 74.0% had coronary
artery disease. Another 74.0% of the study population had history of cerebrovascular
accidents (CVA). Patients with a history of peripheral vascular disease comprised 70.3%
of the study. Patients with a history of diabetes comprised 73.8% of all patients admitted
with heart failure.
Readmissions
The number of readmissions for heart failure steadily increased over the years. In
2002 the 30 day readmission rate was 16.8% while in 2003 through 2008; the rate of
readmissions was 19.0%, 17.6%, 18.4%, 21.4% and 24.8% respectively (Table 2). The
average length of stay of patients admitted for CHF was 5.8 days (SD 4.2 days) with a
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maximum stay of 59 days. During the time of the study, the adherence rate for all the four
heart failure core measures increased steadily from 88.8% to 98.9%.The rate of 30 day
readmissions for heart failure during the same time increased from 16.8% to 24.8%.
Figure 1
Temporal Trends of Adherence to Performance Measures and CHF Readmissions
Readmission
24.8

2008

98.9
21.4

2007

97.3
20.3

2006
Year

All 4 performance measure compliance

2005

18.4

2004

17.6

2003

19

2002

16.8

97.8
98.8
97.4
90.2
88.8
%

Graph of the temporal trends of compliance to all the four performance measures in
relation the rates of CHF readmission during the study period.

Performance Measures
Adherence to heart failure performance measures had improved overtime from
16.8% in 2002 to 24.8% through 2008. This improvement in adherence to the
performance measures over the six year period may be due to a change in government
policy in 2005 resulting in the CMS offering incentives of higher payments to health care
providers adhering to performance measures linked to quality of care. Hospitals are rated
on the quality of care based on these core measures which are also publicly reported. It is
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therefore imperative for hospitals to find ways and means to adhere to these performance
measures in order increase revenue on one hand and to improve their public image as
centers of excellence, on the other hand. Although the general trend was overall
improvement in all the performance measures over time, the smoking cessation core
measure had the greatest increase with 97.8% adherence, while ACEI use core measure
had a 96% adherence rate. The adherence rate for the left ventricular assessment core
measure was 94%. However, the core measure of discharge instruction (at time of
discharge) ranked the lowest at 77.6% over the six years of the study.
Table 2. Number of Patients not Meeting the Core Measures at Discharge
Year

Total
CHF
admissions

Readmissions
(%)

Discharge
instructions
not given

Left
ventricular
function
not
assessed

ACEI not
initiated
at
discharge

Smoking
cessation not
given at
discharge

2008

713

177(24.8)

8

1

0

0

2007

859

184(21.4)

23

0

4

0

2006

866

177(20.3)

19

2

3

1

2005

894

165(18.4)

11

6

8

0

2004

1007

178(17.6)

26

14

11

4

2003

886

169(19.0)

86

23

14

2002

838

141(16.8)

94

26

8

13
8
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Table 3. Statistical Correlations between Adherence to Performance Measures and
Readmissions
Performance Variable
Odds Ratio
95% CI
P value
Left Ventricular Assessment

1.02

1.45-2.63

0.000005

Smoking Cessation

1.03

0.65-1.62

0.89

ACEI usage

1.3

0.98-1.96

0.06

Discharge Instructions

1.02

0.88-1.20

0.76

Heart failure discharge instructions and readmission
Two hundred and sixty-seven (22.3%) of the 1,191 patients readmitted for heart
failure between 2002 and 2008 presented lack of compliance to discharge instructions.
Those patients not readmitted within 30 days (for heart failure) had 22.1% (1071) lack of
compliance to discharge instructions.
There was no significant association between readmission rates and not giving
discharge instructions (OR= 1.02, 95%CI= 0.88-1.20, p= 0.76).
Correlation of smoking cessation and readmission
Among patients readmitted with heart failure during the study period, there were
2.2% (26) who had not received smoking cessation instructions before hospital discharge.
On the other hand, of the 4,865 patients who were not readmitted for heart failure, there
were 2.1% (103) patients who were not given discharge instructions.
There was no association between not receiving a smoking cessation plan at
discharge and the 30 day readmission rate (OR=1.03, 95% CI 0.65-1.62, p=0.89).
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Correlation of ACEI and readmission
In the group of patients who were readmitted for heart failure, 4% (48) did not
receive ACEI therapy, while in the group of patients that were not readmitted within 30
days, 3% (143) did not receive the medications.
Despite a trend towards reduction in the 30 day readmissions associated with
ACEI therapy, there was however no statistical significance in the findings (OR= 1.3,
95% CI 0.98-1.96, p=0.06).
Correlation of LV assessment and readmission
Out of the 1,191 patients readmitted with heart failure, 6% (72) did not have their
left ventricles assessed prior to discharge from the hospital by their physicians. In the
group that was not readmitted, 3.1% (155) did not have left ventricular assessment. There
was a significant relationship between ventricular assessment and readmission (O.R=2,
95% CI 1.45-2.63, p=0.000005).
DISCUSSION:
Readmission to the hospital is influenced by a multitude of factors. Some factors
can be related to social-economic factors. Philbin and colleagues (2001) reported low
social economic status is related to increased readmissions. Patient compliance to
treatment outlined by healthcare providers can also influence the rate of rehospitali
zations (Tsuchihashi et al., 2001). Presence or absence of co-morbid conditions such as
renal failure, chronic obstructive pulmonary diseases may have an effect on the heart
failure readmission rates. Komukai and colleagues (2008) found that preexisting
conditions such as renal failure were associated with increase readmissions to the
hospital. These findings were also confirmed by Burns who reported that multiple past
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hospitalizations secondary to other medical conditions were associated with readmission
to the hospital with CHF (Burns & Nichols, 1991). Anemia in patients with heart failure
was found to be a predictor of early readmission to the hospital and death (Felker et al.,
2003).
Readmissions can also be related to process of care, for instance, when the patient
is not started on evidence based therapies for heart failure. Ashton and colleagues found
that readmissions to the hospital may be an indicator of poor quality care in patients
being treated for heart failure. They reported that patients discharged early from the
hospital prior to complete resolution of symptoms were more likely to be readmitted
within 14 days from discharge (Ashton et al., 1995). Whellan and colleagues (2001) have
proposed that case management in patients with heart failure improves the quality of care
and outcomes. These disease management programs help guide management of patients
with chronic medical conditions by offering a system of coordinated healthcare
interventions.
The CMS links quality of care to 4 performance core measures for heart failure.
These measures include discharge instructions, left ventricular assessment, smoking
cessation counseling and administration of ACEI. In our study, these core measures had
no association with the rate of readmissions to the hospital within 30 days of discharge
from the hospital. The independent relationship of heart failure performance measures
and readmission rate can be attributed to the heterogeneity of the factors influencing
readmissions to the hospital.
Philbin and colleagues (2001) did not find any relationship between early
readmission and the quality of admission work up, evaluation and treatment for heart
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failure patients. In the same study, they reported an association between patient’s clinical
and demographic characteristics with readmissions to the hospital. Patients of lower
social economic class were more likely to be readmitted for heart failure (Philbin et al.,
2001). Even though this study did not show a correlation between adherence to heart
failure performance measures and readmissions, there are some studies that have shown
the contrary. For instance, Chung and colleagues (2008) showed that adherence to heart
failure performance measures reduced all cause heart failure readmissions to the hospital,
although in their study, the sample size was small and the duration of follow up was only
6 months. Even though, Chung’s study showed positive correlation of adherence to the
core measures with readmissions, this did not show any significant association between
the adherence to heart failure performance measures and the 30 day hospital readmission
rates. Some authors have argued that what may be more important is whether patients are
being discharged on the optimal dosages of ACEI, instead of merely documenting that
patients was discharged on an ACEI (McDonald et al., 2001). In his study, he found that
patients who were discharged on the target dosages of ACEI had less readmission rate
within 30 days. In another study by VanSuch and colleagues (2006), adherence to
discharge instructions was associated with reduced readmissions for heart failure.
The lack of effect of the four performance measures (discharge instructions, left
ventricular assessment, smoking cessation counseling and administration of ACEI) on 30
day readmissions may relate to the fact that readmissions for heart failure are influenced
by a heterogeneous group of factors. Two of the four measures, use of ACEI and
smoking cessation take a much longer period of time to demonstrate benefit. For
example, a smoker for 20 years may be counseled on quitting the use of tobacco. The
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process to eventual abstinence may be marked with episodes of recidivism and take years
to attain. Even in the event that the patient has quit smoking, the clinical benefits of
smoking cessation may take much longer than 30 days to realize. ACEI on the other hand
inhibits the hormone angiotensin converting enzyme that has been implicated in the
pathogenesis of heart failure. Inhibition of this enzyme may take weeks before clinical
benefits are seen.
Assessment of left ventricular function may have implications on disease severity
and guide therapy in heart failure. However merely assessing and documenting that
ventricular function was performed during hospitalization does not imply that therapy for
heart failure was optimized. In one study by Luzier et al. (1998), they reported that most
patients discharged with ACEI medications were not on appropriate dosages. In fact, they
reported that heart failure readmissions reduced by up to 28% in patients with ACEI
dosages about 8-10 times higher than the commonly used dosage regimens (Luzier et al.,
1998).
Limitations
There a few limitations of this study that are worthy of mention. One overarching
limitation is that this is a retrospective study and hence, the myriad etiological factors
responsible for readmissions in heart failure patients could not be controlled for. For
instance, infection is a common cause of heart failure exacerbations which can directly
affect readmission. This study did not investigate the reasons for the exacerbation of heart
failure necessitating readmissions to the hospital. Poor compliance to medications is
another reason for recidivism. These and many other specific reasons for heart failure
were not identified in this study. For this reason, our study may have given the false
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impression that heart failure readmission rates are only related to the heart failure
performance measures that we have been studying. There are also patient attributable
factors such as demographic variables, social economic status, coexisting medical
conditions and other psychosocial factors that may influence the rates of readmissions in
heart failure. Provider specific variables such as experience of the attending physician
and whether a cardiologist was involved (or not) in the care of the patient are also
important. These variables can influence the quality of care provided to heart failure
patients and by extension the rates of readmissions. This study did not take into account
the impact of any of these variables on readmissions. This study used existing
administrative data to make inferences on the relationship between performance measures
and readmissions. In one study by Hallerbach and colleagues (2008), they found that in as
many as 50% of all the patients readmitted had been labeled incorrectly, raising serious
questions about using administrative data alone to determine quality of care.
Another limitation of this study is that it was a single center study in a community
hospital serving a predominantly elderly, affluent community. The findings may reflect
the inherent biases of the institution and of its clientele, in which the study was
conducted.
Public Health Policy Implications
This study is expected to shed more light and help us understand the factors
influencing readmissions rates to the hospital in patients with CHF. This knowledge is
important clinically in that it, it would shape clinical care practices that if properly
implemented would lead to improved outcomes in CHF patients, and reduced healthcare
cost.
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There is the perennial debate about the high spiraling cost of healthcare in the US
and a quest for the most effective ways of reducing these healthcare costs while at the
same time ensuring that quality of healthcare is enhanced. Heart failure is the most
common diagnosis with significant contribution to healthcare costs. Finding ways that
improve quality of health and at the same time reduce the cost of care is extremely
important. Heart failure readmissions increase significantly the burden of healthcare
costs. From the public health standpoint, reducing the incidence and prevalence of heart
failure is the ultimate goal. This might be done through risk factor reduction and effective
public health education. However the intermediate goal would be to improve the quality
of life of patients with heart failure both by using evidence based practices and by
improving the process of care that enhances the lives of heart failure patients. Admission
of patients to the hospital is not only an opportunity for clinicians and healthcare
providers to address patients immediate health concerns (that prompted them to seek help
in the first place), but it is also an opportunity for healthcare providers to coordinate
healthcare resources, and to promote educational interventions proven to improve the
quality of lives of patients.
CONCLUSIONS:
This study showed that there was no significant association between hospital’s
adherence to the heart failure performance measures and 30 day readmission rate. There
was a statistically significant relationship between the lack of left ventricular assessment
and readmission rate. There was also a trend towards reduced readmissions in patients
with ACEI although the results were not statistically significant. Left ventricular function
assessment may guide the type of therapy in heart failure patients in that patients with
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low ejection fraction may be initiated on evidence based therapies known to improve
outcomes. Patients with low ejection fraction (cardiac reserve) are candidates for
angiotensin converting enzyme inhibitors, medications that have been shown to have
improved outcomes in heart failure patients. Therefore left ventricular function
assessment may be a surrogate indicator of quality of care in heart failure patients. More
studies should be done to address the relationship between the current heart failure
performance measures and how they relate to quality and outcomes of care in heart
failure patients. Studies should also address current performance measures and whether
they should continue to be used as surrogate indicators for the quality of care and how
these measures impact clinical outcomes. In lieu of the findings of this study, policy
makers should delineate measures that could be labeled as "good practices" for health
care providers from the "core measures". "Good practices" could include among others,
measures such as smoking cessation counseling and discharge instructions given to
patients prior to discharge. These measures while important in guiding healthy behavior
choices in heart failure patients still remain unsubstantiated in terms of hard scientific
evidence in influencing outcomes. Furthermore, these measures are not only variable in
how they are implemented by health care providers but how they may be adopted by
patients. On the other hand, "core measures" should be substantiated to improve
outcomes, measurable and reproducible.
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APPENDIX 1:
Table 1.

CHF RE-ADMISSION DATA EXTRACTION SHEET

MEDICAL RECORD NUMBER

DURATION OF HOSPITAL STAY

AGE
SEX
BMI
PAST MEDICAL HISTORY:
DM: HTN:CAD: CVA:CKD:PVD:
MEDICATIONS:
PREADMISSION MEDICATIONS
SMOKING : Yes / No
LABS: Creatinine: BMP: Cardiac
enzymes
2D ECHO: EF
STRESS TEST: Positive: Neg
CATHETERISATION
DISCHARGE MEDICATIONS:
ACEI, BB, ASA,ARB
DISCHARGE PLANNING AT
DISCHARGE
DISCHARGE INSTRUCTIONS: Yes/No

SMOKING CESATION GIVEN Y/N
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APPENDIX 2

Table 2. ABBREVIATIONS
ABBREVIATIONS

MEANING

ACEI

Angiotensin converting enzyme inhibitor

AMI

Acute Myocardial infarction

ARB

Aldosterone Receptor blocker

BMI

Body Mass Index

BNP

Brain Naturetic Peptide

CAD

Coronary Artery Disease

CKD

Chronic Kidney disease

CVA

Cerebrovascular accidents

DM

Diabetes Mellitus

ECHO

Echocardiography

EF

Ejection fraction

HTN

Hypertension

PVD

Peripheral vascular Disease
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APPENDIX 3
Performance measures for Left ventricular function
Performance

Measure Description

Measure

Criterion Met or

Rate Calculation

Acceptable Alternative

Evaluation of

Heart failure patients

Documentation that left

Numerator: Heart

Left

with documentation in

ventricular systolic function

failure patients with

Ventricular

the hospital record that

was evaluated before arrival,

documentation in the

Systolic (LVS)

left ventricular systolic

during hospitalization, or

hospital record that

Function

(LVS) function was

was planned for after

LVS was evaluated

(previously

evaluated before arrival,

discharge. Exclusions

before arrival, during

called “Left

during hospitalization,

include patients with reasons

hospitalization, or is

Ventricular

or was planned for after

documented by a physician,

planned for after

Function (LVF)

discharge

nurse practitioner or

discharge

physician assistant for no

Denominator: Heart

LVS assessment.

failure patients age 18

Assessment”)

and older
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APPENDIX 4
Performance measure for ACEI
Performance Measure

Measure Description

Criterion Met or Acceptable Alternative

ACE Inhibitor or Angiotensin

Heart failure patients
with left ventricular
systolic dysfunction
(LVSD) and without
both Angiotensin
converting enzyme
inhibitor (ACE
inhibitor) and
Angiotensin Receptor
Blocker (ARB)
contraindications who
were prescribed an ACE
inhibitor or an ARB at
hospital discharge

Documentation that an ACE inhibitor or an
ARB was prescribed at discharge in patients
with LVSD who were not participating in an
ACE inhibitor alternative clinical trial at the
time of discharge and where there is no
documentation of one or more of the
following potential contraindication/reason
for not prescribing an ACE inhibitor or an
ARB at discharge:
• ACE inhibitor allergy and ARB
allergy
• Moderate or severe aortic stenosis
• Other reasons documented by a
physician, nurse practitioner, or physician
assistant for not prescribing an ACE
inhibitor and not prescribing an ARB at
discharge
LVSD is defined as documentation of a left
ventricular ejection fraction (LVEF) less
than 40% or a narrative description of left
ventricular function (LVF)

Receptor Blocker (ARB) for
Left Ventricular Systolic
Dysfunction (LVSD)
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APPENDIX 5
Performance measure for Discharge instructions
Performance Measure

Measure Description

Criterion Met or

Rate Calculation

Acceptable
Alternative
Discharge Instructions

Heart failure patients
discharged home with
written instructions or
educational material
given to patient or care
giver at discharge or
during the hospital stay
addressing all of the
following: activity
level, diet, discharge
medications, follow-up
appointment, weight
monitoring, and what
to do if symptoms
worsen

Documentation that
heart failure patients
discharged to home,
home care or home IV
therapy, or their care
givers were given
written discharge
instructions or other
educational materials
addressing all of the
following: activity
level, diet, discharge
medications, follow-up
appointment, weight
monitoring, and what
to do if symptoms
worsen

Numerator: Heart
failure patients with
documentation that
they or their care givers
were given written
discharge instructions
or other educational
material addressing all
of the following:
activity level, diet,
discharge medications,
follow-up appointment,
weight monitoring, and
what to do if symptoms
worsen Denominator:
Heart failure patients
age 18 and older
discharged home
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APPENDIX 6
Performance measures for Smoking cessation
Performance

Measure

Criterion Met or Acceptable

Measure

Description

Alternative

Adult Smoking

Heart failure
patients with a
history of smoking
cigarettes, who are
given smoking
cessation advice or
counseling during a
hospital stay

Documentation that for heart
failure patients who are
smokers (defined as someone
who has smoked any time
during the year prior to
hospital arrival), smoking
cessation advice or counseling
was provided during the
hospital stay

Cessation
Advice/
Counseling

Rate Calculation

Numerator: Heart failure
patients (cigarette smokers)
who receive smoking cessation
advice or counseling during the
hospital stay Denominator:
Heart failure patients age 18
and older with a history of
smoking cigarettes anytime
during the year prior to hospital
arrival
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APPENDIX 7

Kettering Health Network

From: "Gail.Young@khnetwork.org" <Gail.Young@khnetwork.org>
To: sulamazi@yahoo.com
Cc: Gail.Young@khnetwork.org
Sent: Tue, June 30, 2009 9:11:04 AM
Subject: Study 09-019: Impact of Congetive Heart Failure Discharge Planning on
Congestive Heart Failure Re-Admission Rates

NWPRO23-09
June 24, 2009
Sula Mazimba, M.D.
South Dayton Acute Care Consultants
33 West Rahn Road, Suite 102
Dayton, Ohio 45429
RE: Your letter dated: 6/22/2009
09-019: Impact of Congetive Heart Failure Discharge Planning on Congestive
Heart Failure Re-Admission Rates
Dear Dr. Mazimba:
I have reviewed your request for the new study listed above. This study
qualifies as exempt from review under the following guideline: [45 CFR
46.101(b)(4)] because the research involves existing data and subjects cannot be
identified. The following items are exempt from review:
o Protocol Version 1.1 (dated 6/22/2009)
o Data Collection Tool (dated 6/4/2009)
Your study has been granted a waiver from the requirement to secure
authorization for the use of PHI.
Should you make any changes to the procedures or project, please submit the
revisions to the KHN IRB for review and determination prior to
implementation.
Upon completion of your project, please complete and submit a final report in
addition to any resulting publications or reports.
You are free to conduct your study without continuing reviews by Kettering
Health Network (KHN) IRB.
Thank you for keeping the Board informed of your activities. If you have any
Version Number: 1.1
Version Date: 6/22/2009

Protocol Template
Effective Date: 7/25/2007
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questions or need further information, please contact Gail Young ((937) 395-8309;
fax (937) 395-8185; email: Gail.Young@khnetwork.org).
Sincerely,
Douglas Lehrer, M.D.
Vice Chairperson, Institutional Review Board
Enclosure: Application for Waiver of Authorization or Altered Authorization
Under the HIPAA Privacy Rule (dated 6/4/2009)
cc: IRB Files, Innovation Center

Version Number: 1.1
Version Date: 6/22/2009

Protocol Template
Effective Date: 7/25/2007

Page 50 of 55

51

Institutional Review Board
RESEARCH PROTOCOL

TO:

Kettering Health Network Institutional Review Board

FROM:

Principal Investigator: Sula Mazimba, M.D.
Phone Number / Fax Number: 937-901-0215
Mail Address: 33 W Rahn Rd, Suite 102
Kettering, Ohio 45429
Email Address:

DATE:

sulamazi@yahoo.com

6/22/09

STUDY TITLE: Impact of Congestive Heart Failure Discharge Planning on Congestive Heart
Failure Re-Admission Rates
VERSION # 1.1

Version Number: 1.1
Version Date: 6/22/2009

Protocol Template
Effective Date: 7/25/2007
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Impact of Congestive Heart Failure Discharge Planning on Congestive Heart Failure
Re-Admission Rates

Study Summary
In this study, we hypothesize that the addition of the Congestive Heart Failure (CHF)
discharge planning team has improved the rate of CHF readmission in the hospital. Via
retrospective chart review, we will review the rate of readmission before and the rate of
readmission after the introduction of the discharge planning for CHF.

Purpose
The purpose of this study is to assess the impact of discharge planning on the readmission
rates for CHF and to assess compliance to recommended medications for CHF treatment.

Background and Significance
CHF is the most common inpatient diagnosis in the USA. It contributes to about 35
billion dollars every year in health care costs. The bulk of the cost is due to readmission
of patients. Discharge planning has been shown to improve patient adherence to
discharge medications and compliance, and this may have an impact on re-admissions.
The CHF discharge planning team was initiated in KMC in October 2006.This study aims
to evaluate the impact of this program to preventing readmissions in the hospital.

Human Subject Population
Method of Subject Identification and Recruitment
All patients between the ages of 18-89 presenting to Kettering Medical Center with a
CHF diagnosis between January 1, 1999 and December 4, 2008 will be reviewed in a
retrospective fashion. Records will be sourced by ICD code 428.0. Patient charts
will be identified by assigning a number to the patient only if they meet the inclusion
criteria. Only deidentified data will be used in this study.
Gender of Subjects
Males Only

Females Only

Both Males and Females

Number of Subjects
Up to 2000 subjects may be enrolled at KHN.
Age Range of Participants
The age range of patients for this study will be 18-89 years old.
Inclusion/Exclusion Criteria
Inclusion Criteria
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o Patients between the ages of 18 and 89
o Patients readmitted to Kettering Medical Center between 1999 and June 4,
2009 with a diagnosis of CHF
Exclusion Criteria
Patients under the age of 18 and over the age of 89 are excluded due to
privacy concerns
○ No readmission for CHF to KMC
○

Vulnerable Subjects
N/A

Research Design and Methods
All patients between the ages 18-89 presenting to Kettering Medical Center between
January 1, 1999 and December 4, 2008 will be reviewed in retrospective fashion as
described above in the “Method of Subject Identification and Recruitment”. Only data
existing in the medical record on or before June 4, 2009 will be reviewed. Only those
who fit our inclusion criteria will be considered. We will review the chart to record the
following information: age, sex, BMI, past medical history of HTN, DM, CAD, CVA,
CKD, PVD, Smoking, Labs like blood sugar, creatinine, cardiac enzymes, BNP, 2D Echo
EF, stress test, catheterization, duration of hospital stay, preadmission and discharge
medications, number of readmissions in 6 months as well as 6 months follow up (AMI,
CVA, and death). The aim of the study is to look at the rate of readmissions in the
patients with CHF before and after the implementation of discharge planning.

Surveys / Interviews / Questionnaires
No patient surveys, interviews, or questionnaires will need to be completed for this study.

Risks / Discomforts / Benefits
Risks: There is little-to-no risk associated with this retrospective study. The data
collection and storage processes will be protected as indicated by HIPAA guidelines.
The recruitment process will be limited to diagnosis code and no individual consent will
be necessary. No form of deception will be used in this study.
Benefits: The potential benefit of this study will be to help understand the factors
influencing readmissions in patients with CHF and would eventually help us know if
implementation of proper discharge planning can reduce the rate of readmissions in them

Data Analysis and Data Monitoring
No ongoing data monitoring will occur as this is a retrospective study. All data will be
analyzed by the Principal Investigator.
Version Number: 1.1
Version Date: 6/22/2009
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Data Storage and Confidentiality
All data will be stored on a password protected computer accessible only to study
personnel. Data collected will be void of any identifying characteristics to prevent
linking data to patients. When the data collection and study analysis is completed, all
data will be permanently deleted.

Estimated Period of Time to Complete the Study
The estimated time to complete this study will be 12 months to allow time for data
collection and analysis.

Informed Consent
Subjects’ written, signed consent will be obtained.
Waiver of a signed consent is requested.
Waiver or alteration of consent is requested.

No
No
Yes

Justifications for the request to waive signed consent are listed as follows:
 The research involves no more than minimal risk to subjects as review of
medical records is for limited information.
 Subjects’ rights and welfare will not be affected by the waiver because the
subjects are not being deprived of any clinical care in this retrospective
review.
 The research could not practicably be conducted without the waiver as it is
not feasible to locate approximately 2000 subjects to obtain consent what
would not affect care they have already received
 Subjects will not be provided with additional information because
subjects’ care has already been completed for the study/condition. The
research results will not benefit subjects or change what has already
occurred.

Grant Application
N/A

Study Budget
For this study we request a waiver of IRB fees.
All other costs incurred for study supplies and time for data collection and analysis will
be incurred by Principal Investigator.

Attachments
Version Number: 1.1
Version Date: 6/22/2009

Protocol Template
Effective Date: 7/25/2007
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Data Collection Tool
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